High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma

H. A. Rossi, P. S. Becker, R. V.B. Emmons, P. Westervelt, W. Levy, Q. Liu, Y. Clark, K. Ballen

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

Allogeneic stem cell transplantation (SCT) has been shown to be a curative therapy for some patients with non-Hodgkin's lymphoma (NHL). Total-body irradiation and high-dose cyclophosphamide combinations are the most established conditioning regimens used in this setting. We examined the efficacy and toxicity of cyclophosphamide, BCNU, and VP-16 (CBV) as a suitable chemotherapy-only regimen for NHL patients. In total, 18 patients, median age 42 years, with NHL were treated with CBV followed by allotransplant. Patients had received a median of two prior chemotherapy regimens. Median times to neutrophil and platelet recovery were 19 and 15 days, respectively. Interstitial pneumonitis occurred in one patient. There have been four relapses after a median follow-up of 39 months. Overall, there were four deaths, one because of relapse. The 2-year estimates of relapse-free and overall survival are 56 and 76%, respectively. CBV is a safe and an effective alternative to TBI-containing regimens before allogeneic SCT for NHL.

Original languageEnglish
Pages (from-to)441-446
Number of pages6
JournalBone Marrow Transplantation
Volume31
Issue number6
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Keywords

  • Allogeneic
  • Carmustine
  • Conditioning therapy
  • Non-Hodgkin lymphoma
  • Stem cell transplantation

Fingerprint Dive into the research topics of 'High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this